GlassScriptPhysician profile
Brian C Mattsson
NPI 1538564653
$3,961.83
in general payments reported to CMS, 2019-2025
27 companies · $14.40 in 2025
The $14.40 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $1,964 · 2023: $1,326 · 2024: $50.09 · 2025: $14.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,350 · Education: $40.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.17 |
| Education | $40.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $811.77 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $654.35 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $476.35 | 2021-2024 | |
| Lilly USA, LLC | $472.01 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Corcept Therapeutics | $247.79 | 2022-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $238.65 | 2021-2023 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $186.06 | 2022-2023 | |
| Dexcom, INC. | $168.33 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $118.07 | 2021-2022 | |
| Abbott Laboratories | $113.77 | 2022-2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $64.65 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $47.77 | 2023 | |
| Kyowa Kirin, INC. | $42.67 | 2023 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $41.80 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $37.54 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35.35 | 2022 | |
| Abbvie INC. | $26.76 | 2022-2023 | |
| Halozyme INC | $24.22 | 2023 | |
| Zealand Pharma US, INC. | $22.75 | 2021 | |
| Radius Health, INC. | $21.88 | 2023 | Tymlos |
| Amryt Pharma Holdings LTD | $21.72 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.87 | 2022 | |
| Merck Sharp & Dohme LLC | $17.16 | 2021 | |
| Madrigal Pharmaceuticals | $14.40 | 2025 | Rezdiffra |
| Antares Pharma, INC. | $13.96 | 2021 | |
| Amarin Pharma, INC. | $12.72 | 2021 | |
| Beta Bionics, INC. | $11.46 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mattsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.